According to the deal, Hyglos will leverage Lonza’s patent-protected recombinant factor C technology in the production of endotoxin products.
As part of the settlement, Lonza will cancel a previously filed law suit against Hyglos.
Hyglos general manager Dr Wolfgang Mutter said, "We are convinced that Hyglos’ innovative assays, entirely based on recombinant molecules, are addressing important needs of endotoxin testing laboratories worldwide."
Lonza Bioscience head Dr Teun Van der Heide said, "Endotoxin detection using recombinant factor C instead of Limulus amoebocyte lysates has recently been acknowledged by the FDA as an alternative method. We believe that this sustainable animal-free alternative will be the future of endotoxin detection."